Exchange: NASDAQ·Updated 06:18 PM EDT
BMRN logo

BMRNBiomarin Pharmaceutical Inc. - Registered Shares

$59.20
$0.08
(0.14%)
Today
Closed $59.20
$0.00
(0.00%)
After Hours
EarningsAug 3
Mkt Cap$11.43B
Vol1.59M
News
all
press releases
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for...
PR Newswire
News Placeholder
More News
News Placeholder
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.
Zacks
News Placeholder
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
BridgeBio Pharma's Attruby sales are surging, but can growth keep justifying its premium valuation amid execution risks and rising costs?
Zacks
News Placeholder
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.
Zacks
News Placeholder
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 PR Newswire SAN RAFAEL, Calif., June 16, 2026 Data from an...
PR Newswire
News Placeholder
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years...
Yahoo! Finance: News
News Placeholder
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development...
Yahoo! Finance: News
<
1
2
...
>

Advertisement|Remove ads.